The positive interim data from the Phase I/II trial of AMT-130 indicates that the treatment is generally well-tolerated and shows preserved function compared to the natural history of Huntington's disease. This supports the continuation of clinical development and potential late-stage regulatory interactions, which could positively impact uniQure's stock price in the short term.